Dataset Information

GNPS - Colgate facial cleanser longitudinal study_Skin samples

ABSTRACT: MS/MS spectra were collected from face of 6 individuals before and during 2 weeks of application of a Colgate facial cleanser. During weeks 1-4 of washout period, volunteers did not use any personal beauty product and they washed their face only with water. During the following 2 weeks, all participants applied the Colgate facial cleanser daily on their face. Samples were collected at the end of the washout period on week 4. During facial cleanser application (weeks 5 and 6), samples were collected once a week (beginning of week 5 and end of week 6) right after the first usage then 4, 8 and 24 hours after the first usage. For each timepoint, 9 samples were collected from different locations on the face.

INSTRUMENT(S): maXis

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Pieter Dorrestein

PROVIDER: MSV000082432 | GNPS | Fri Jun 01 15:08:00 BST 2018

REPOSITORIES: GNPS

ACCESS DATA

Similar Datasets

Project description:<p>Andersen-Tawil syndrome (ATS) is an ion channel disorder that causes episodes of muscle weakness and potentially life-threatening heart arrhythmias. The majority of ATS cases are caused by a mutation in the KCNJ2 gene, which is linked to potassium channels in the heart, brain, and skeletal muscle; other cases are presumed to be caused by an undetermined gene lesion. To date, the treatment for ATS has been largely anecdotal, and no treatments have been formally assessed in a controlled clinical trial. This study will determine whether potassium supplements and/or acetazolamide, which is a diuretic medication, affect the duration of muscle weakness and heart rhythm abnormalities in people with ATS.</p> <p>Participation in this study will last about 11 months. Participants will first attend a 3-day inpatient visit that will include a medical history, physical examination, blood work, heart rhythm testing by an electrocardiogram (ECG) and Holter monitor, strength testing, a health questionnaire, and daily potassium supplementation. Participants will also track the number and length of weakness episodes that they experience while in the hospital. On the last day of the inpatient visit, participants will be provided with multiple bottles containing either potassium or placebo. Participants will then return home for an 18-week treatment period that will consist of six 3-week-long treatments of either potassium or placebo, with the treatment schedule being randomly determined. Upon completing the first 18-week treatment period, participants will attend a second 3-day inpatient visit that will include the same tests and procedures as the first. The only difference will be that participants will receive acetazolamide along with potassium. This will be followed by a second 18-week treatment period that will consist of six 3-week-long treatments of either acetazolamide or placebo. At the end of the second treatment period, participants will fill out another health questionnaire. Throughout both 18-week treatment periods, participants will phone in daily to track any muscle or heart problems. They will also provide blood samples on a weekly basis. At Weeks 2, 5, 8, 11, 14, and 17 of both treatment periods, participants will wear a Holter monitor for 24 hours and then mail it in. A final outpatient visit will occur 8 weeks after the end of the second treatment period and will include heart rhythm testing, muscle strength testing, and blood work.</p>

Dataset Information

GNPS - Colgate facial cleanser longitudinal study_Skin samples

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure